Form 4: NextCure Director Elaine V. Jones Granted 18,700 Stock Options

NextCure, Inc. Director Elaine V. Jones was granted 18,700 stock options with an exercise price of $0.47 per share, aligning her interests with the company's performance.

Summary

• Elaine V. Jones, a Director of NextCure, Inc. (NXTC), was granted 18,700 stock options.
• The options have an exercise price of $0.47 per share.
• The grant date for these options was June 20, 2025.
• Each option represents the right to buy one share of NextCure Common Stock.
• The options are set to expire on June 19, 2035.
• The options will vest in full on the earlier of June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Following this transaction, Elaine V. Jones beneficially owns 18,700 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a standard, positive event of a director receiving equity compensation, which aligns their interests with the company's performance. There are no negative implications or risks disclosed within this specific filing.

Positives

• The grant of stock options to Director Elaine V. Jones aligns her financial interests with the long-term performance and shareholder value of NextCure, Inc.

Future Outlook

The stock options granted to Director Elaine V. Jones are set to vest in full by June 20, 2026, or the date of the 2026 Annual Meeting of Stockholders, indicating a future commitment period for the director's equity compensation.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, including companies like NextCure, Inc., to incentivize long-term commitment and align leadership interests with shareholder returns. This type of compensation is a standard component of executive and director remuneration packages across various sectors.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice across publicly traded companies, including those in the biotech sector like NextCure, Inc. This aligns director incentives with long-term shareholder value.
• The vesting schedule, which includes a full vest by the next annual meeting or a specific date, is typical for director equity grants, ensuring continued engagement and oversight.
• The exercise price of $0.47, while specific to this grant, is consistent with options granted at or near the market price on the grant date, a common industry standard for incentive options.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.

Next Steps

• The stock options will vest in full on the earlier of June 20, 2026, and the date of the 2026 Annual Meeting of Stockholders.
• The options can be exercised by the director at any time after vesting until their expiration date of June 19, 2035.

Key Dates

Keywords

NextCure, NXTC, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant